Skip to Content

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial CTSUUROC90203-M


A randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer

Principal Investigator(s)

John Murray


  • Protocol No. CTSUUROC90203-M
  • Open Date: 11/05/2007
  • Staging: Phase III
  • Age Group: Adults
  • Scope: National
  • Objective: To determine whether treatment with neoadjuvant docetaxel and androgen deprivation therapy prior to radical prostatectomy will increase the rate of 3-year biochemical progression -free survival (bPFS) compared to treatment with immediate radical prostatectomy alone for high-risk prostate cancer patients
  • Disease Sites: Prostate
  • Therapies: Chemotherapy - cytotoxic; Hormonal Therapy; Surgery
  • Drugs: None Specified
  • Participating Institutions: Baptist Hospital; Meharry Medical College
  • Secondary Protocol No: CTSU 90203


None Provided.


Not provided. Please call for more information.